A detailed history of Huntington National Bank transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Huntington National Bank holds 305 shares of TGTX stock, worth $10,696. This represents 0.0% of its overall portfolio holdings.

Number of Shares
305
Previous 289 5.54%
Holding current value
$10,696
Previous $5,000 40.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$17.21 - $25.28 $275 - $404
16 Added 5.54%
305 $7,000
Q2 2024

Aug 08, 2024

SELL
$13.32 - $19.19 $4,329 - $6,236
-325 Reduced 52.93%
289 $5,000
Q1 2024

May 03, 2024

BUY
$13.02 - $21.3 $2,408 - $3,940
185 Added 43.12%
614 $9,000
Q4 2023

Feb 07, 2024

SELL
$6.68 - $18.81 $4,482 - $12,621
-671 Reduced 61.0%
429 $7,000
Q3 2023

Nov 08, 2023

BUY
$8.36 - $26.5 $4,965 - $15,741
594 Added 117.39%
1,100 $9,000
Q2 2023

Aug 11, 2023

BUY
$15.48 - $35.0 $7,832 - $17,710
506 New
506 $12,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $5.09B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Huntington National Bank Portfolio

Follow Huntington National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Huntington National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Huntington National Bank with notifications on news.